

## Technology Appraisal Committee Meeting (Committee D)

**Minutes:** **Confirmed**

**Date and Time:** **Wednesday 26 October 2016, 10am – 2.15pm**

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Professor Gary McVeigh, Chair 2. Dr Lindsay Smith, Vice Chair 3. Professor David Bowen 4. Dr Matthew Bradley 5. Dr Ian Davidson 6. Professor Simon Dixon 7. Susan Dutton 8. Gillian Ells 9. Professor Paula Ghaneh 10. Dr Susan Griffin 11. Professor John Henderson 12. Sumithra Maheswaran 13. Dr David Meads 14. Mr Malcolm Oswald 15. Dr Paula Parvulescu 16. Dr Mohit Sharma	Present for all notes Present for all notes
-----------------	---	---

### **In attendance:**

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Sophie Cooper	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 13
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Carole Longson	Centre Director, National Institute for Health and Clinical Excellence	Present for notes 14 to 25
Fay McCracken	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 14 to 25

Nicola McMeekin	Aberdeen HTA Group	Present for notes 14 to 25
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Emily Richards	Assistant Project Manager, National Institute for Health and Care Excellence	Present for all notes
Alex Sexton	Administrator, National Institute for Health and Care Excellence	Present for all notes
Thomas Strong	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 14 to 25
Nwamaka Umeweni	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 13
Dr Olivia Wu	Aberdeen HTA Group	Present for notes 14 to 25

**Non-public observers:**

Natalie Brooks	Project Manager, National Institute for Health and Clinical Excellence	Present for notes 1 to 13
Ann Greenwood	National Institute for Health and Clinical Excellence	Present for all notes
Linda Landells	Associate Director, National Institute for Health and Clinical Excellence	Present for notes 14 to 25
Louise Miller	Data analyst, National Institute for Health and Clinical Excellence	Present for all notes
Helen Powell	Technical Analyst, National Institute for Health and Clinical Excellence	Present for notes 14 to 25

Samantha Shannon	Project Manager, National Institute for Health and Clinical Excellence	Present for all notes
Frances Sutcliffe	Associate Director, National Institute for Health and Clinical Excellence	Present for notes 14 to 25
Maroulla Whiteley	Business Analyst, National Institute for Health and Clinical Excellence	Present for all notes

## **Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of sofosbuvir-velpatasvir for treating chronic hepatitis C and pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
2. Apologies were received from Dr Aomesh Bhatt, Dr Andrew Black, Dr Ian Campbell, Tracey Cole and Professor Femi Oyebode.

## **Any other Business**

3. None

## **Appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C**

### **Part 1 – Open session**

4. The Chair welcomed company representatives from Gilead Sciences to the meeting.
5. The Chair asked all Committee members to declare any relevant interests
  - 5.1. Dr David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Susan Dutton, Gillian Ells, Professor Paula Ghaneh, Professor John Henderson, Sumithra Maheswaran, Professor Gary McVeigh, Dr David Meads, Malcolm Oswald, Dr Paula Parvulescu, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.
  - 5.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken research for a comparator company on unrelated topics. He was not

directly involved in the work and the University of Sheffield received payment for the work.

5.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.

5.3. Dr Susan Griffin declared a non-personal specific financial interest as her team was involved in a scoping project to look at treatment of hepatitis C in the UK. The University for which Dr Griffin works was remunerated for this work.

5.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.

6. The Chair asked all NICE Staff to declare any relevant interests.

6.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.

7. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

8. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

9. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.

10. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

11. Discussion on confidential information continued. This information was supplied by the company.

12. The Committee continued to discuss the clinical and cost effectiveness of Sofosbuvir-velpatasvir for treating chronic hepatitis C.

12.1. The committee decision was based on consensus.

13. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy

### Part 1 – Open session

14. The Chair welcomed the invited experts, Nicola McMeekin and Olivia Wu, to the meeting and they introduced themselves to the Committee.
15. The Chair welcomed company representatives from Merck Sharp and Dohme to the meeting.
16. The Chair asked all Committee members to declare any relevant interests
  - 16.1. Dr David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Susan Dutton, Gillian Ells, Professor Paula Ghaneh, Sumithra Maheswaran, Professor Gary McVeigh, Dr David Meads, Malcolm Oswald, Dr Paula Parvulescu, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
  - 16.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken research for comparator companies on unrelated topics. He was not directly involved in the work and the University of Sheffield received payment for the work.
    - 16.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
  - 16.3. Dr Susan Griffin declared a personal non-specific financial interest as she had taken part in an advisory board related to non-small cell lung cancer and was personally reimbursed by a comparator company.
    - 16.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.
  - 16.4. Professor John Henderson declared a non-personal non-specific financial interest as his institution had received research funding from a comparator company, and a personal non-specific financial interest as he had received an honorarium from a comparator company for an educational talk on an unrelated topic.
    - 16.4.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.
17. The Chair asked all NICE Staff to declare any relevant interests.
  - 17.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

18. The Chair asked all other invited guests to declare their relevant interests.
  - 18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
19. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
20. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
21. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
22. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

23. Discussion on confidential information continued. This information was supplied by the company.
24. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
  - 24.1. The committee decision was based on consensus.
25. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

26. Thursday 24 November 2016, from 10am – 5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.